REPORTS

Let’s Pullulate and Expand Your Business

Type 1 Diabetes Therapeutics Market - Global Professional Analysis and Forecast to 2026

Oct 10, 2019  |  176 PAGES  |  REPORT CODE: CMM202449
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Type 1 Diabetes Therapeutics market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.9% during the forecast period.

This report presents the market size and development trends by detailing the Type 1 Diabetes Therapeutics market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Type 1 Diabetes Therapeutics market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Type 1 Diabetes Therapeutics industry and will help you to build a panoramic view of the industrial development.

Type 1 Diabetes Therapeutics Market, By Type:

  • Rapid acting insulin analogs

  • Long acting insulin analogs

  • Premix insulin analogs

Type 1 Diabetes Therapeutics Market, By Application:

  • Patient

  • Hospital

  • Others

Some of the leading players are as follows:

  • Merck＆Co., Inc.

  • Macrogenics, Inc.

  • B.Braun Melsungen AG

  • Biodel, Inc.

  • Novartis AG

  • AstraZeneca plc

  • Novo Nordisk

  • Johnson＆Johnson

  • DiaVacs, Inc.

  • Eli Lilly and Company

  • Sanofi SA

  • Boehringer Ingelheim GmbH

  • XOMA Corp.

  • Takeda Pharmaceutical Company Limited

  • GlaxoSmithKline plc

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Type 1 Diabetes Therapeutics Market: Technology Type Analysis

  • 4.1 Type 1 Diabetes Therapeutics Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Type 1 Diabetes Therapeutics Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Rapid acting insulin analogs

    • 4.3.2 Long acting insulin analogs

    • 4.3.3 Premix insulin analogs

5 Type 1 Diabetes Therapeutics Market: Product Analysis

  • 5.1 Type 1 Diabetes Therapeutics Product Market Share Analysis, 2018 & 2026

  • 5.2 Type 1 Diabetes Therapeutics Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Type 1 Diabetes Therapeutics Market: Application Analysis

  • 6.1 Type 1 Diabetes Therapeutics Application Market Share Analysis, 2018 & 2026

  • 6.2 Type 1 Diabetes Therapeutics Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Patient

    • 6.3.2 Hospital

    • 6.3.3 Others

7 Type 1 Diabetes Therapeutics Market: Regional Analysis

  • 7.1 Type 1 Diabetes Therapeutics Regional Market Share Analysis, 2018 & 2026

  • 7.2 Type 1 Diabetes Therapeutics Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Merck＆Co., Inc.

    • 9.1.1 Merck＆Co., Inc. Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Macrogenics, Inc.

    • 9.2.1 Macrogenics, Inc. Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 B.Braun Melsungen AG

    • 9.3.1 B.Braun Melsungen AG Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Biodel, Inc.

    • 9.4.1 Biodel, Inc. Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Novartis AG

    • 9.5.1 Novartis AG Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 AstraZeneca plc

    • 9.6.1 AstraZeneca plc Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Novo Nordisk

    • 9.7.1 Novo Nordisk Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Johnson＆Johnson

    • 9.8.1 Johnson＆Johnson Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 DiaVacs, Inc.

    • 9.9.1 DiaVacs, Inc. Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Eli Lilly and Company

    • 9.10.1 Eli Lilly and Company Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Sanofi SA

    • 9.11.1 Sanofi SA Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Boehringer Ingelheim GmbH

    • 9.12.1 Boehringer Ingelheim GmbH Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 XOMA Corp.

    • 9.13.1 XOMA Corp. Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Takeda Pharmaceutical Company Limited

    • 9.14.1 Takeda Pharmaceutical Company Limited Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 GlaxoSmithKline plc

    • 9.15.1 GlaxoSmithKline plc Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

 

The List of Tables and Figures (Totals 109 Figures and 148 Tables)

  • Figure Rapid acting insulin analogs Type 1 Diabetes Therapeutics market, 2015 - 2026 (USD Million)

  • Figure Long acting insulin analogs Type 1 Diabetes Therapeutics market, 2015 - 2026 (USD Million)

  • Figure Premix insulin analogs Type 1 Diabetes Therapeutics market, 2015 - 2026 (USD Million)

  • Figure Patient market, 2015 - 2026 (USD Million)

  • Figure Hospital market, 2015 - 2026 (USD Million)

  • Figure Others market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Type 1 Diabetes Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table North America Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table North America Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table North America Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Canada Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Canada Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Europe Type 1 Diabetes Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table Europe Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Europe Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Europe Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Germany Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Germany Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table France Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table France Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Italy Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Italy Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Spain Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Spain Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Type 1 Diabetes Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table China Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table China Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Japan Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Japan Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table India Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table India Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Type 1 Diabetes Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table MEA Type 1 Diabetes Therapeutics market, by country, 2015 - 2026 (USD Million)

  • Table MEA Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table MEA Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table MEA Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Type 1 Diabetes Therapeutics market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Type 1 Diabetes Therapeutics market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Type 1 Diabetes Therapeutics market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Merck＆Co., Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Macrogenics, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table B.Braun Melsungen AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biodel, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca plc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Johnson＆Johnson Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table DiaVacs, Inc. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eli Lilly and Company Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi SA Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Boehringer Ingelheim GmbH Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table XOMA Corp. Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Takeda Pharmaceutical Company Limited Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GlaxoSmithKline plc Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top